LB→RLS

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/182,183	05/23/1994	LEU-FEN H. LIN	SYNE225/C4-U	8424

S-225E

21069 7590 06/10/2002

AMGEN INCORPORATED
MAIL STOP 27-4-A
ONE AMGEN CENTER DRIVE
THOUSAND OAKS, CA 91320-1799

EXAMINER
HAYES, ROBERT CLINTON

ART UNIT	PAPER NUMBER
1647	

DATE MAILED: 06/10/2002

DOCKETED
Notice to Comply
7-10-02

Request Term Disc. to be filed.

Please find below and/or attached an Office communication concerning this application or proceeding.

JUN 18 2002

PTO-90C (Rev. 07-01)

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
08/182,183			

EXAMINER	
ART UNIT	PAPER NUMBER
	54

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

To clarify the record, the copy of the after final amendment that was filed on 8/15/00, but not previously matched with the case, is **not** considered as timely under 37 CFR 1.8(a) & (b) because the statutory period for filing a Brief ended **7/14/00**. However, because new grounds of rejection are now necessitated (i.e., as it relates to an obvious double patenting rejection over U.S. Application No. 08/451374; now U.S. Patent 6,093,802), all previously allowed claims are no longer allowed, and the finality of the Office action mailed 6/15/99 is hereby withdrawn in view of the new grounds of rejection. See MPEP 706.07(f)(O).

Additionally, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. For example, no amino acid SEQ ID NO for Fig. 22 exists, as required, and the text has not been amended to describe what new SEQ ID NOs: 27-28 entail or whether these sequences are even necessary and should otherwise be deleted from the Raw Sequence Listing. In summary, 37 CFR 1.821 (a)(2)(d) states that *each sequence disclosed* must appear separately in the "Sequence listing", and referenced appropriately *in the text of the description* and the claims. See MPEP 2422 & 2431. Therefore, the following changes to the specification must also be made:

page 8, line 1: change to "pre-pro" and mature forms
page 8, line 3: insert and residue numbers 1-134 of SEQ ID NO: 4)
page 8, line 4: delete [amino acids residues 1 to 134 of SEQ ID NO: 5 and]
page 8, line 6: change (SEQ ID NO: [5] 6)
page 8, line 7: -no aa sequence exists for the Fig. 22, as required
page 8, line 31: delete [mature]
page 11, line 6: insert purified rat GDNF
page 11, line 12: insert (residue numbers 1-25 of SEQ ID NO: 4)
page 11, line 12: change Figure [19] 13
page 11, line 26: insert purified rat GDNF
page 11, line 36: insert residue numbers 1-134 of SEQ ID NO: 4
page 11, line 37: insert mature rat GDNF
page 13, line 20: insert Residue numbers 1-134 of SEQ ID NO: 6 depicts

page 26, line 22: insert (residue numbers 1-134 of SEQ ID NO: 4)
page 27, line 36: change positions [518] 541 and [538] 561 , etc.
page 30, line 16: change (residue numbers 1-134 of SEQ ID NO: 4)
page 30, line 16: change (residue numbers 1-134 of SEQ ID NO: [5] 6)
page 30, line 18: delete [(SEQ ID NO:5)]
page 30, line 19: change and 22 (SEQ ID NO:[8] 25)
page 69, line 4: insert residue 51 (SEQ ID NO: 25)
page 70, line 1: insert human pre-proGDNF (SEQ ID NO: 26)

Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Note that Applicants will need to request that the terminal disclaimer of 8/15/00, etc. be entered after compliance with the Sequence Rules is fulfilled.

Any inquiry concerning this communication should be directed to Examiner **Robert C. Hayes**, Art Unit **1647**, whose telephone number is **703-305-3132.**

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Robert C. Hayes, Ph.D.
May 29, 2002

GARY L. KUNZ
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

Application No.: 08/182,183

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- [X] 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- [ ] 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- [ ] 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- [ ] 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- [ ] 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- [ ] 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- [ ] 7. Other: _____

Applicant Must Provide:

- [X] An ~~initial or~~ substitute computer readable form (CRF) copy of the "Sequence Listing".
- [X] An ~~initial or~~ substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- [X] A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
PatentIn Software Program Support (SIRA)
Technical Assistance.....703-287-0200
To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE